The Marietta, GA-based Medical - Products firm has earned a 97 Earnings Per Share rating. Its earnings increases in the 3 latest quarterly comparisons through Sep '17 were above the +25% minimum guideline (C criteria). Earnings rose +17%, +75%, +40% and +33% in the Dec '16. Mar, Jun, and Sep '17 quarterly comparisons, respectively, versus the year ago periods while sales revenues during that span rose +35%, +36%, +33%, and +31%. Annual earnings growth (A criteria) has been strong since turning a profitable 2014, after years of shrinking losses.
The number of top-rated funds owning its shares rose from 248 in Mar '17 to 308 in Dec '17, a reassuring sign concerning the I criteria. There are 111 million shares outstanding. The current Up/Down Volume Ratio of 1.3 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness rating of C and a Sponsorship rating of C.
Charts courtesy wwwstockcharts.com